Institutes focus on large initiatives to directly improve and impact cancer care. Moffitt currently has one institute, the DeBartolo Family Personalized Medicine Institute (DFPMI). It was established in 2012 with a vision to bring personalized medicine to the point of care.
Moffitt is a world leader in precision cancer interception research. Precision cancer interception is a new paradigm that actively combats cancer at earlier points via personalized prevention, screening and treatment based on a person's unique biological and behavioral characteristics. To advance this area, Moffitt created a cutting-edge research facility, Population Engagement and Research Laboratory (PEARL).
Providing oversight for Moffitt Cancer Center’s Total Cancer Care® Study, the DFPMI seeks to create and share targeted treatments. Our personalized medicine efforts are also addressing the side effects of therapies, quality of life issues, symptom control and patient preferences. The Institute is supported by a generous donation from the DeBartolo family.